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Abstract-V,,,, and K,,, values with twenty-five “atypical” and thirty-seven “usual” cholinesterase human 
sera were determined for the cholinesterase substrates procaine, tetracaine, benzoylcholine, o-nitro- 
phenylbutyrate, cu-naphthylacetate and aspirin. Aspirin was demonstrated to be a substrate for serum 
cholinesterase. For each of these substrates the ratio of V,,substrate to V,,,, benzoylcholine was found 
to be similar with atypical and usual cholinesterase sera. Therefore, we concluded that the respective 
turnover numbers for atypical and usual cholinesterase were the same. Both atypical and usual 
cholinesterase sera had turnover numbers of 255 min-’ for procaine, 74 min-i for tetracaine, 
7200 min-’ for aspirin in the presence of 50 mM CaClr, 36,000 min-’ for cu-naphthylacetate, and 
48,000 mini for o-nitrophenylbutyrate, at 25” in 0.1 M Tris-Cl buffer, pH 7.4. A comparison of K,,, 
values for atypical and usual cholinesterase indicated that the positively charged substrates, as well as 
aspirin in the presence of CaClr, showed a lower affinity with atypical than with usual cholinesterase, 
while neutral esters had nearly the same K, for atypical and usual cholinesterase. These results imply 
that individuals with atypical cholinesterase will hydrolyze therapeutic doses of positively charged 
substrates and aspirin at reduced rates, but neutral substrates should be hydrolyzed at normal rates. 
The clinical importance of serum cholinesterase (EC 
3.1.1.8; acylcholine acyl-hydrolase; also known as 
pseudocholinesterase and butyrylcholinesterase) was 
first recognized when certain patients developed res- 
piratory paralysis for several hours after receiving 
normal doses of succinylcholine. These patients 
hydrolyzed the drug very slowly because they had 
inherited an “atypical” cholinesterase, which has a 
much lower affinity for succinylcholine, than does 
“usual” cholinesterase [ 1, 21. Based upon this phar- 
macogenetic explanation for succinylcholine sensi- 
tivity, one might predict that individuals with atypical 
cholinesterase would also show considerable reduc- 
tion in the rates of hydrolysis of other drugs known 
to be substrates for the enzyme. For example, Kalow 
[3] as well as Foldes et al. [4] have suggested that 
atypical cholinesterase patients might be more sus- 
ceptible to certain local anesthetics. 
In the present report the possibility of increased 
drug sensitivity of individuals with atypical cholin- 
esterase was investigated by means of in vitro bio- 
chemical studies.. Sera from patients with atypical 
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cholinesterase, as well as from normal individuals, 
were characterized with respect to their affinities 
(K,,, values) and maximum velocities of enzymatic 
hydrolysis (V,,,, values) with various ester substrates. 
The compounds selected for study are known to be 
substrates of cholinesterase in human serum, and no 
other esterase in human serum contributes signifi- 
cantly to their hydrolysis [5-81. The substrates were 
classified according to their net charge at pH 7.4, 
and it was found that neutral compounds were dis- 
tinguished as a group from all other substrates, in 
that only neutral compounds had the same K,,, value 
for both atypical and usual cholinesterases. 
METHODS 
Cholinesterase. Frozen sera from thirty-seven peo- 
ple of the “usual” cholinesterase genotype and 
twenty-five people of the “atypical” cholinesterase 
genotype were used for these studies. The samples 
were selected to give a broad range of activities and, 
therefore, do not represent the average activity level 
in each population. Cholinesterase genotype was 
assigned on the basis of the characteristic dibucaine 
number [l], fluoride number [9], and activity with 
benzoylcholine [lo]. 
Activity assays. All assays were carried out in a 
recording spectrophotometer (the Gilford 2000 or 
Beckman DBG) whose cuvette compartment was 
maintained at 25”. The buffer for activity assays with 
benzoylcholine was 0.067 M phosphate, pH 7.4; the 
buffer for all other substrates was 0.10 M Tris-Cl, 
pH 7.4. All chemicals were from the Sigma Chemical 
Co., St. Louis, MO, except aspirin which was from 
the Mallinckrodt Chemical Works, St. Louis, MO. 
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Benzoylcholine HCl hydrolysis was measured at 
240 nm (Ae = 6700 M-’ cm-‘) by the method of 
Kalow and Lindsay [lo], over the range 12.5 to 
50 PM; serum dilution in the assays was 1: 100. o- 
Nitrophenylbutyrate was dissolved in methanol, and 
a stock solution of 1.0 mM was prepared according 
to the method of Huggins and Lapides [ll]. Pro- 
duction of o-nitrophenol was followed at 410 nm 
(E = 2970 M-’ cm-‘); the serum dilution in the 
assays was 1:300. The concentrations of o-nitro- 
phenylbutyrate ranged from 0.08 to 0.80 mM. 
Hydrolysis of procaine HCl was observed at 305 nm 
(E = 12,200 M-’ cm-‘) and hydrolysis of tetracaine 
HCI at 325 nm (E = 13,500 M-’ cm-‘); serum dilu- 
tion was 1: 30. For assays with atypical cholinester- 
ase, the procaine concentrations ranged from 20 to 
100 PM, and the tetracaine concentrations from 6.25 
to 50 PM. For assays with usual cholinesterase, the 
procaine concentrations ranged from 2.5 to 6.7 ,uM, 
and the tetracaine concentrations from 0.17 to 
1.0 m. Aspirin (acetylsalicylic acid) hydrolysis was 
measured at 300 nm (E = 3500 M-’ cm-‘) in the 
presence of 50 mM calcium chloride, over the range 
4 to 31 mM; serum dilution in the assays was 1: 15. 
A stock solution of 50 mM aspirin at pH 7.4 was 
prepared by adding an equivalent amount of NaOH 
in a dropwise manner to a rapidly stirring mixture 
of aspirin and buffer. Only freshly prepared (no 
more than 20 min old) aspirin solutions were used 
because aspirin rapidly decomposed in solution, and 
its product, salicylate, interfered with the rate assays 
due to its high U.V. absorbance. The use of older 
aspirin solutions gave artifically slow rates of 
hydrolysis. The spontaneous rate of aspirin hydroly- 
sis was subtracted from the rate observed in the 
presence of enzyme. a+Naphthylacetate hydrolysis 
was monitored at 321 nm (E = 2220 M-’ cm-‘) over 
the range 0.25 to 1.0 mM; all assays contained 6.6% 
ethanol and a serum dilution of 1: 30. The procedure 
was essentially the same as that of Zapf and Coghlan 
[12] except that we measured initial rates. 
RESULTS 
Hydrolysis ofaspirin. Hofstee [5] reported in 1951 
that human serum cholinesterase hydrolyzed aspirin. 
Hofstee worked with serum and not with pure 
enzyme. The evidence identifying the enzyme as 
cholinesterase was its inhibition by 10e5 M eserine, 
by organophosphates, and by acetylcholine. In our 
present work, prior to measuring rates of aspirin 
hydrolysis by serum, we determined that pure chol- 
inesterase, prepared as described [13, 141, hydro- 
lyzed aspirin. We also compared the rates of aspirin 
hydrolysis by pure cholinesterase and by serum and 
found that cholinesterase accounted for at least 90 
per cent of the enzymatic degradation of aspirin by 
serum. Thus we have provided new evidence iden- 
tifying cholinesterase as “aspirinase”. A separate 
manuscript on aspirin hydrolysis is in preparation. 
Maximum rates of substrate hydrolysis by atypical 
and usual cholinesterase. The maximum velocity of 
substrate hydrolysis, V,,,,, was determined for each 
compound from a Lineweaver-Burk plot for each 
individual serum sample. The observed maximum 
velocities of hydrolysis of benzoylcholine by the usual 
and atypical cholinesterases were correlated with the 
V,,,,value when procaine, tetracaine, o-nitrophenyl- 
butyrate, a-naphthylacetate or aspirin was the sub- 
strate (Fig. 1). The slopes of the lines relating the 
V,,,, for benzoylcholine hydrolysis to the 1/,, values 
for hydrolysis of the other substrates were not sig- 
nificantly different for the atypical and the usual 
cholinesterases (at the P < 0.05 level) as shown in 
Table 1. Regression analysis of the data id Fig. 1 
Substrate 
Cholinesterase 
genotype* N Slopet (r) t-Statistic* 
Procaine AA 12 0.0088 (0.80) 1.44 
uu 18 0.013 (0.86) 
AA & UU pooled 30 0.017 (0.95) 
Tetracaine AA 12 0.0052 (0.73) 0.565 
uu 19 0.0065 (0.78) 
AA & UU pooled 31 0.0049 (0.86) 
o-Nitrophenylbutyrate AA 10 3.4 (0.67) 0.20 
uu 15 3.7 (0.95) 
AA & UU pooled 25 3.2 (0.86) 
cu-Naphthylacetate AA 10 3.1 (0.94) 1.35 
uu 14 2.2 (0.90) 
AA & UU pooled 24 2.4 (0.92) 
Aspirin AA 6 0.54 (0.95) 0.63 
uu 8 0.46 (0.96) 
AA & UU pooled 14 0.48 (0.86) 
* Atypical choline&erase genotype is designated AA; the usual is UU. Atypicals and usuals 
were treated as one group in “AA & UU pooled”. 
t The slope and correlation coefficient (r) were determined by linear regression using the V,,,, 
for benzoylcholine hydrolysis as the independent variable and the V ma.value with the other substrate 
as the dependent variable. The units of slope are pmoles of substrate hydrolyzed, at the V,,,,,, per 
min per ml divided by the pmoles of benzoylcholine hydrolyzed, at the V,,,, per min per ml. 
$ A test for non-parallelism of the slopes of the atypical versus the usual cholinesterase was 
done by calculation of a t-statistic. None of the t values found was significant at the P < 0.05 level 
for degrees of freedom = n, + nz - 4. 
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Fig. 1. Maximum rates of substrate hydrolysis by atypical and usual cholinesterase sera. Each point 
represents one serum sample. Key: (X) atypical cholinesterase; and (0) usual cholinesterase. V,,,,was 
determined for each compound from a Lineweaver-Burk plot for each serum sample. Vmis expressed 
as pmoles . min-’ . (ml serum)‘. The set of serum samples is different in each graph. 
Table 1. Thus, the relationship between the V,,,,for 
benzoylcholine hydrolysis and the V,,,,,for hydrolysis 
of the other substrates was similar for both atypical 
and usual cholinesterases. Atypical and usual chol- 
in&erase were treated as one group in order to 
estimate best the relationship between V,,,,x for ben- 
zoylcholine hydrolysis and that for hydrolysis of the 
other substrates; this pooled value for slope is also 
shown in Table 1. The turnover numbers for these 
substrates were calculated from the “AA & UU 
pooled” slopes in Table 1 and are listed in Table 2. 
Since the slopes of the lines for the atypical and 
usual cholinesterases were not significantly different, 
it may be concluded that the turnover number for 
atypical cholinesterase was the same as the turnover 
number for usual cholinesterase for each of these 
substrates; that is, the moles of substrate hydrolyzed 
per min per mole active site, measured under con- 
ditions where the substrate was saturating, was the 
same for the atypical and the usual cholinesterases. 
K, values. A comparison of K,,, values of atypical 
and usual cholinesterase (Table 2) demonstrated that 
atypical cholinesterase had a higher K,,,than the usual 
cholinesterase for positively charged substrates (qua- 
ternary and tertiary amines). Likewise, atypical chol- 
inesterase had a higher K,,, for aspirin; a negatively 
charged substrate, in the presence of 50 mM CaClr. 
It is likely that aspirin forms a complex with calcium, 
having a net positive charge. In contrast, atypical 
and usual cholinesterases had nearly identical K,,, 
values for neutral substrates. Thus, atypical chol- 
inesterase had a lower affinity for benzoylcholine, 
succinyldithiocholine, heroin, procaine, tetracaine, 
and aspirin complexed with CaCb, than did usual 
cholinesterase. 
This pattern of K,,, values was disturbed by (Y- 
naphthylacetate. In the absence of added calcium, 
atypical cholinesterase had a Km of 0.37 mM for this 
substrate, whereas usual cholinesterase had a Km of 
1.0 mM, which is two and one-half times higher. 
This result confirms a similar observation reported 
by Bamford and Harris [8]. The Km values, however, 
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are nearly identical for both enzyme genotypes in 
the presence of 20 mM calcium chloride. 
Calcium chloride stimulation. Figure 2 shows that 
20 mM CaCh stimulated the observed rate of 1y- 
naphthylacetate hydrolysis by usual cholinesterase 
at all acnaphthylacetate concentrations tested. The 
extrapolated V,,,ax rate, however, was the same with 
or without calcium chloride. Thus, calcium chloride 
affected the K,,,, but not the V,,,,,, for usual cholin- 
esterase when the substrate was Lu-naphthylacetate. 
In contrast, the activity of atypical cholinesterase 
with ~naphthylacetate was unaffected by the addi- 
tion of calcium chloride, so that Km and V,, were 
the same whether activity was measured in 10 mM 
EDTA or in 20 mM CaCl2. 
Aspirin hydrolysis was also stimulated by calcium 
chloride. In contrast to the results with wnaphthy- 
lacetate, calcium chloride stimulated the hydrolysis 
of this substance by both atypical and usual chol- 
inesterases. The spontaneous rate of aspirin hydroly 
sis in 0.1 M Tris-Cl buffer, pH 7.4, was not affected 
by 50 mM calcium chloride. 
Calcium chloride (20 mM) also stimulated the 
hydrolysis of o-nitrophenylbutyrate, a neutral sub- 
strate, by usual choli~esterase (data not shown), but 
did not affect the rate of benzoylcholine hydrolysis 
in 0.1 M Tris-Cl buffer, pH 7.4. 
Substrate inhibition. High concentrations of pos- 
itively charged substrates, including benzoylcholine, 
procaine and tetracaine, inhibited the usual cholin- 
esterase. The atypical cholinesterase, however, did 
not exhibit substrate inhibition. Thus, when the 
activities of atypical and usual cholinesterases were 
tested with 50 PM tetracaine, the rate of hydrolysis 
by atypical cholinesterase was faster because, at this 
con~n~ation of tetracaine, the usual cholinesterase 
was inhibited 55 per cent. At concentrations below 
1 PM tetracaine, the rate of hydrolysis by atypical 
cholinesterase was slower than by usual cholinester- 
ase. This observation is consistent with the lower 
affinity (K,,,) of atypical cholinesterase for tetracaine. 
No substrate inhibition was observed with the 
neutral coInpounds within the concentration range 
tested, a range that was limited by the relative insolu- 
bility of these compounds in aqueous buffers. 
Comparison of atypical and usual cholinesterase 
activities measured at a single concentration of sub- 
strate. Figure 3 shows that atypical and usual sera 
fell into two distinct groups when activity with ben- 
zoylcholine was compared with activity with o-nitro- 
phenylbutyrate. Atypical cholinesterase appeared to 
have more o-nitrophenylbutyrate activity per unit of 
benzoylcholine activity that did usual cholinesterase. 
This result agrees with a similar observation reported 
by McComb et al. [17]. Yet Fig. 1C shows that 
atypical and usual cholinesterase sera did not fall 
into two groups when activities were measured at 
V,,,,. The discrepancy between the two comparisons 
exists because the K,,, for benzoylcholine was higher 
for atypical than for usual cholinesterase, whereas 
the K,,,for o-nitrophenylbutyrate was similar for both 
enzymes. Thus, when assays were done at one sub- 
strate concentration, as in Fig. 3, the atypical chob 
inesterase sera segregated into a group distinct from 










Quatemary amine esters 
Benzovlcholine 0.004 0.022 1.0 15,000 
Succ&ldithiocholine~ 0.035 1.08 0.0553 830 








20 mM CaCh 
0.11 0.45 0.0333 500 
0.0066 0.10 0.017 255 
0.00014 0.008 0.0049 74 
0.33 0.4 ::: 48,000 
1.0 0.37 36,000 
0.4 0.37 2.4 36,000 
Negatively charged ester 
Aspirin + 50 mM CaClz 4.2 16 0.48 7200 
* K,,, and V,,,, values were determined from Lineweaver-Burk plots, using individual human sera. 
The buffer was 0.1 M Tris-Cl. nH 7.4, 25” for all substrates except benzoylcholine and heroin, which 
were assayed in 0.067 M phos&hate, pH 7.4. 
t The ratio V,,,, substratelVm, benzoylcholine is the slope for “AA & UU pooled” from Table I. 
The values for succinyldithiochoii~e and heroin are from Refs. 15 and 16 respectively. 
$ Turnover number was defined as moles substrate hydrolyzed per min per mole active site, at V,,,, 
conditions. Turnover number for benzoylcholine was determined by Lockridge and La Du 1131 using 
highly purified usual and atypical cholinesterases. For all other substrates, turnover number was 
calculated by multiplying the benzoylcholine value of 15,000 mm’ times the ratio V,,,, substrate/V,, 
benzovlcholine. 
8 From Hersh et al. [15]. 
I] From Lockridge et al. [16]. Highly purified usual and atypical chohnesterases, rather than sera, 
were used. 
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Fig. 2. Differential effect of calcium chloride on cu-naphthy- 
lacetate hydrolysis by atypical and usual cholinesterase 
sera. Panel A: Lineweaver-Burk plot showing the rates of 
hydrolysis of various concentrations of cu-naphthylacetate 
(1 to 0.25 mM) by one atypical cholinesterase serum, in 
the presence of 10 mM EDTA (X), or 20 mM CaClz 
(El), or with no addition (0). The buffer was 0.1 M 
T&-Cl, pH 7.4, at 25”. K,,, = 0.42 mM; V,,, = 
2.0 moles. min-’ * (ml serum)-‘. Panel B: Lineweaver- 
Burk plot of the hydrolysis of cu-naphthylacetate by one 
usual cholinesterase serum, in the presence of 10 mM 
EDTA (X) or with no addition (0). K,,, = 1.0 mM; 
v-= 2.0 poles.min-‘. (ml serum)-‘. In the presence 
of 20 mM CaClz (U), K,,, = 0.38 mM, and V,,,, = 
2.0 poles * min-’ * (ml serum)-‘. Twelve other sera (six 
atypical and six usual) were also tested and gave similar 
results. 
the usual sera. When V,, values were measured, 
however, the benzoylcholine activity of atypical chol- 
inesterase increased to the level of usual cholinester- 
ase, as shown in Fig. 1C. 
Inhibition by tetramethylammonium chloride. 
Inhibition studies with tetramethylammonium were 
done to test the hypothesis that the major difference 
between the atypical and usual cholinesterase 
involved an alteration in the anionic binding site on 
the atypical cholinesterase [2, 13, 181. The results 
are presented in Table 3. When the substrate was 
positively charged (benzoylcholine and procaine), 
the positively charged inhibitor, tetramethylammon- 
ium chloride, was much more effective with usual 
than with atypical cholinesterase, as reflected by the 
ratio of Ki values. When the substrate was a neutral 
ester (o-nitrophenylbutyrate and cu-naphthylace- 
tate), tetramethylammonium chloride inhibited both 
usual and atypical cholinesterases with nearly the 
same potency-that is, the ratio of Ki values was 
approximately 1. With neutral substrates, inhibition 
by tetramethylammonium chloride appeared to be 
due to nonspecific ionic-strength effects, as indicated 
by the very high apparent Kivalues of 0.4 to 0.8 M, 
an interpretation supported by the observation of 
Huggins and Lapides [ll] that 0.5 M NaCl inhibited 
p-nitrophenyl propionate hydrolysis by 70 per cent. 
Comparison of K,,, values (see Table 2) shows that 
the positively charged substrates, like the positively 
charged inhibitor, bound more tightly to usual chol- 
inesterase than to atypical cholinesterase, whereas 
the neutral substrates bound with nearly the same 
affinity to both usual and atypical cholinesterase. 
These results are consistent with the conclusion that 
the anionic site was altered in atypical cholinesterase 
in such a way that it bound positively charged com- 
pounds poorly. 
DISCUSSION 
We are interested in defining the types of drugs 
that are likely to cause adverse reactions in individ- 
uals with atypical cholinesterase and the types that 
may have normal effects. We examined, therefore, 
the difference between atypical and usual cholin- 
esterases, first, in their intrinsic abilities to hydrolyze 
substrates, a quality measured by the turnover num- 
ber and, second, in their affinities for a series of 
esters, as measured by K,,,. 
Table 3. Tetramethylammonium chloride inhibition of hydrolysis of various substrates by 
usual and atypical cholinesterase (ChE) sera* 
Substrate 
Apparent Ki (M) 
Atypical ChE Usual ChE Ki ratio (A/U) 






0.08 0.01 8.0 
0.043 co.01 >4.3 
0.82 0.39 2.1 
0.65 0.43 1.53 
* Tetramethylammonium chloride was used as an inhibitor at 0.1 M, 0.25 M and 0.5 M 
in 0.1 M Tris-Cl, pH 7.4. The apparent Ki values were evaluated from Dixon plots where 
the inhibition appeared to be competitive. 
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Fig. 3. Comparison of atypical and usual cholinesterase 
activities measured at a single concentration of substrate. 
Activities of fourteen usual (0) and twelve atypical (X) 
cholinesterase sera were measured using 50 PM benzoyl- 
choline and 0.66 mM o-nitrophenylbutyrate. Activities are 
expressed as moles hydrolyzed. min-’ . (ml serum)-‘. 
We found that atypical and usual cholinesterases 
had the same turnover number with each of a variety 
of substrates, whether that substrate was positively 
charged, neutral, or negatively charged. Earlier stud- 
ies by Lockridge and La Du [13] with three com- 
pounds had demonstrated that highly purified atyp- 
ical and usual cholinesterases had identical turnover 
numbers. The present report, utilizing sera rather 
than purified enzymes, extends this conclusion to 
include several additional compounds. The values 
for the turnover numbers reported in Table 2 would 
not be correct if enzymes other than cholinesterase 
hydrolyzed these substrates in serum. Though the 
assumption has been made that cholinesterase is the 
only enzyme in serum that contributes significantly 
to hydrolysis of these substrates, there may be doubt 
regarding the validity of this assumption. Thus, the 
turnover values in Table 2 are not as reliable as 
turnover numbers measured with pure cholinester- 
ase. The conclusion that atypical and usual cholin- 
esterase have the same turnover number is indepen- 
dent of the actual value assigned to turnover number 
in Table 2, and it, therefore, does not rely on the 
validity of the above assumption. Furthermore, this 
conclusion is supported by a third line of evidence. 
We measured the cholinesterase protein concentra- 
tion in twenty atypical sera and twenty-eight usual 
sera by immunological methods* and found that the 
turnover number for benzoylcholine and for o-nitro- 
phenylbutyrate, when based on ,ug enzyme protein 
titrated with antibody, was the same for atypical and 
usual cholinesterase sera. 
Since the turnover numbers of atypical and usual 
cholinesterase are the same, one can attribute a 
difference in V,,,, per ml serum to a difference in 
enzyme concentration; that is to say, a low V,,,, 
reflects a low enzyme concentration and a high V,,,, 
reflects a high cholinesterase concentration. Vmaxper 
* H. W. Eckerson, A. Oseroff, 0. Lockridge and B. N. 
La Du, unpublished results. 
ml serum was found by Bamford and Harris [8] and 
by Hersh et al. [15] to be similar, on the average, 
for sera containing atypical or usual cholinesterase. 
From their results we calculated that the concentra- 
tion of atypical cholinesterase molecules in serum 
is about 75-85 per cent of the concentration of usual 
cholinesterase molecules. Immunochemical titra- 
tions of atypical and usual cholinesterases in sera 
have led to a similar conclusion [19]. In our labora- 
tory* immunodiffusion studies showed that sera 
classified as atypical had about 70 per cent of the 
cholinesterase concentration found in usual sera. 
The K,,,values for all compounds, except aspirin, 
have been reported previously. Our values are sim- 
ilar to those of Davies et al. [20] for benzoylcholine, 
Kalow [6] and Foldes et al. [21] for procaine and 
tetracaine, Bamford and Harris [8] for cy-naphthy- 
lacetate, and McComb et al. [17] and Whittaker and 
Hardisty [22] for o-nitrophenylbutyrate, though 
strict comparisons cannot be made because buffer 
composition and temperature were, in many cases, 
different. Our observation that the affinities of atyp- 
ical and usual cholinesterase are nearly identical for 
those substrates that are neutral esters provides an 
exception to the widely held generalization [20] that 
atypical cholinesterase has a lower affinity for all 
compounds. 
That calcium chloride affects the K,,, for neutral 
compounds and for aspirin has not been reported 
previously, though Hofstee [5] did show that the rate 
of aspirin hydrolysis by human serum increased in 
the presence of CaC12. The differential effect of 
20 mM calcium chloride on the hydrolysis of (Y- 
naphthylacetate by atypical and usual cholinesterase 
can be used as another means of discriminating 
between the two genotypes. 
The biochemical difference between atypical and 
usual cholinesterase may be a single amino acid 
mutation at the anionic site, as proposed by Kalow 
and Davies [2]. Muensch et al. [18] suggested that 
the mutation was from a negatively charged (Glu or 
Asp) to a positively charged residue (Arg or Lys). 
Our findings and those of Lockridge and La Du [13] 
agree with this hypothesis. That atypical and usual 
cholinesterase have the same turnover number and 
the same K,,, for neutral substrates but a different 
K,,,for positively charged substrates suggests that the 
esteratic sites are the same, but the anionic site is 
altered on atypical cholinesterase. Our tetramethyl- 
ammonium chloride inhibition studies also support 
this conclusion. 
The well-known succinylcholine sensitivity of 
atypical cholinesterase patients leads to a concern 
that these patients may also be sensitive to other 
drugs. Our results predict that neutral substrates of 
serum cholinesterase will be hydrolyzed nearly as 
rapidly in patients with atypical cholinesterase as in 
those with the usual type of enzyme. On the other 
hand, choline esters and their ana1ogs-e.g. procaine 
and tetracaine, as well as aspirin-are expected to 
be hydrolyzed more slowly by patients with atypical 
cholinesterase because in vivo concentrations of 
drugs will be low and will, therefore, reflect the 
decreased binding affinity of atypical cholinesterase. 
This expectation has been substantiated by Raj et 
al. [23] who measured the level of chloroprocaine 
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in the blood of patients after lumbar-epidural as well 
as brachial plexus blocks. The patient with atypical 
cholinesterase maintained high levels of chloropro- 
Caine much longer than did other patients. However, 
this did not cause toxicity in the atypical cholinester- 
ase patient, and the duration of block was not longer. 
Tetracaine was reported by Smith and Foldes [24] 
to be hydrolyzed more rapidly, in vitro, by atypical 
than by usual cholinesterase (0.23 vs 0.20 pmoles 
per hr per ml plasma). We have shown that this 
result is true only under the special circumstance of 
high tetracaine concentration (50 PM) in which the 
usual cholinesterase undergoes marked substrate 
inhibition. Substrate inhibition was not observed 
with atypical cholinesterase. At low tetracaine con- 
centrations, such as might be expected in therapeutic 
situations, the atypical cholinesterase hydrolyzes 
tetracaine more slowly due to its lower affinity for 
tetracaine. 
Despite the theoretical possibility that the local 
anesthetics, including procaine and chloroprocaine, 
might cause toxicity in atypical cholinesterase indi- 
viduals [3, 41, we know of only two reports linking 
atypical cholinesterase with toxicity to local anes- 
thetics. In the report by Downs [25], the patient was 
assumed to have atypical cholinesterase because of 
a history of succinylcholine apnea. The atypical chol- 
inesterase genotype, however, cannot be assigned 
with certainty on the basis of succinylcholine apnea, 
since only about 50 per cent of all apneic patients 
have atypical cholinesterase [26]. In the report by 
Zsigmond and Eilderton [27], the patients definitely 
had atypical cholinesterase, but the local anesthetics 
that caused toxicity were not identified. Thus, neither 
report firmly links atypical cholinesterase with tox- 
icity to procaine or to any other ester-type local 
anesthetic. 
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